SCHEDULE: RTW Investments Reports 5.2% Stake in Oruka Therapeutics

RTW Investments, LP and Roderick Wong, M.D. have filed a Schedule 13G, confirming beneficial ownership of 3,139,030 shares, representing 5.2% of Oruka Therapeutics, Inc. common stock.

Summary

• RTW Investments, LP, an investment adviser, and its Managing Partner, Roderick Wong, M.D., have filed a Schedule 13G.
• This filing confirms their beneficial ownership of 3,139,030 shares of Oruka Therapeutics, Inc. common stock.
• This ownership stake represents 5.2% of the total outstanding shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
• The filing is dated August 14, 2026, with the event date requiring the filing being June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily confirms a passive investment stake and does not contain operational or financial performance updates.

Positives

• Confirms a significant passive investment stake (5.2%) by RTW Investments in Oruka Therapeutics.
• The investment is stated to be in the ordinary course of business, suggesting a standard portfolio holding rather than a hostile action.

Negatives

• The filing does not provide any operational or financial performance data for Oruka Therapeutics.
• It is a passive filing and does not indicate any new strategic initiatives or positive developments from the company itself.

Risks

• The filing does not explicitly mention any risks associated with Oruka Therapeutics.
• However, as a passive investment, the value of RTW Investments' stake is subject to the overall performance and market perception of Oruka Therapeutics.

Future Outlook

This filing is a confirmation of beneficial ownership and does not contain forward-looking statements or guidance regarding Oruka Therapeutics' future performance.

Management Comments

• The filing should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates RTW Investments' interest in Oruka Therapeutics as a passive investment, which is typical for investment advisers managing funds.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive stake, which could be viewed positively as institutional support, but it does not provide information on the company's performance that would directly impact share value.
• Management of Oruka Therapeutics: The filing is a standard disclosure and does not directly impact management's operational control, as the investment is passive.

Next Steps

• RTW Investments, LP and Roderick Wong, M.D. will file subsequent amendments to this Schedule 13G as necessary.
• The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

Key Dates

Keywords

Oruka Therapeutics, RTW Investments, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Passive Investment